Latham Advises on BioVersys’ CHF 213 Million IPO

Latham & Watkins has advised Citigroup Global Markets Limited, UBS Investment Bank, and Stifel Europe AG on the initial public offering (IPO) of BioVersys, a multi-asset, clinical-stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria. The IPO was priced at CHF 36.00 per share, implying a market capitalization at listing of CHF 213 million, and is the first biotech listing in Switzerland since 2018.

The shares will be listed on the SIX Swiss Exchange and trade under the ticker symbol “BIOV.”

The Latham team was led by London corporate partner Ryan Benedict, with Milan Capital Markets Lawyer Irene Pistotnik and Frankfurt associate Alexandre Maturana.